1  dose of the neuromuscular facilitatory drug edrophonium.

2                                              Edrophonium (10 mg) had no significant effect on action

3 ompounds, establishes a relationship between edrophonium acceleration of oxime-induced reactivation o

4 eterminant, as characterized with respect to edrophonium and decamethonium.

5 jects with a positive chest pain response to edrophonium and in none of the 5 subjects with a negativ

6  the binding of classical inhibitors such as edrophonium and propidium or inhibitors that are current

7  subjects (before and after 80 microgm/kg of edrophonium), and under 3 study conditions in the NCE pa

8  the binding of ligands such as huperzine A, edrophonium, and acridines and one end of bisquaternary

9 ted esophageal chest pain were studied after edrophonium chloride injection to provoke symptoms.

10                 The weakness was reversed by edrophonium, consistent with a myasthenic disorder.

11                                              Edrophonium, decamethonium, and propidium, three quatern

12 e, 9-amino-1,2,3,4-tetrahydroacridine (THA), edrophonium (EDR), and other structurally diverse inhibi

13 l cord to the acetylcholinesterase inhibitor edrophonium (EDR).

14                          In normal subjects, edrophonium induced an increase in the CM and LM contrac

15 sm of the post-tetanic potentiation (PTP) or edrophonium-induced facilitatory response involves the o

16 Furthermore, when the acylation site ligands edrophonium or m-(N, N,N-trimethylammonio)trifluoroaceto

17 ed a dose-related suppression of PTP and the edrophonium response indicative of a suppression of moto

18 ide showed that in the presence of 50 microM edrophonium, the reactivation rate constants increased 3